Severity of depression continuous measures ‐ HDRS total score at the end of the treatment · patients with depression during opioid agonist treatment for opioid dependence
1 finding from 1 review
Adverse events ‐ Withdrawn for medical reasons · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants probably leads to higher adverse events ‐ Withdrawn for medical reasons compared with placebo according to any definition (moderate certainty).
1 finding from 1 review
Dropout · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in dropout compared with placebo (moderate certainty).
1 finding from 1 review
Severity of depression dichotomous measures ‐ "very much" or "much" improved on the Clinical Global Impression Scale · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants may leads to higher severity of depression dichotomous measures ‐ "very much" or "much"… compared with placebo (low certainty).
1 finding from 1 review
> 50% reduction in depressive symptoms · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in severity of depression dichotomous measures ‐ >50% reduction in… compared with placebo (low certainty).
1 finding from 1 review
Quality of sleep · adults with insomnia
1 finding from 1 review
Adverse events · adults with insomnia
1 finding from 1 review
Sleep efficiency · adults with insomnia
1 finding from 1 review
Leaving the study early · adults with panic disorder
Tricyclic antidepressants probably leads to lower total number of dropouts compared with placebo (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · adults with panic disorder
Tricyclic antidepressants may leads to lower failure to remit compared with placebo (low certainty).
1 finding from 1 review
panic symptoms · adults with panic disorder
2 findings from 1 review
Withdrawals due to adverse events · adults with panic disorder
Tricyclic antidepressants probably leads to higher number of dropouts due to adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Outcomes (2‐6 months post‐treatment) · adults with panic disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to respond at endpoint (6‐12 weeks) · adults with panic disorder
Tricyclic antidepressants probably leads to lower failure to respond compared with placebo (moderate certainty).
1 finding from 1 review
Quality of sleep · adults with insomnia
1 finding from 1 review
Adverse events (at 4, 6 or 12 weeks) · adults with insomnia
Tricyclic antidepressants showed no clear difference in adverse events (at 4, 6 or 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Sleep onset latency ‐ not reported · adults with insomnia
1 finding from 1 review
Sleep efficiency · adults with insomnia
1 finding from 1 review
Total sleep time, next night; · adults with insomnia
1 finding from 1 review
FatigueMeasured at end of treatment, 26 weeks · men and women aged over 18 years with chronic fatigue syndrome
1 finding from 1 review